SAT0099 JOINT DAMAGE PROGRESSES IN DAS28 REMISSION AND IS DRIVEN BY RESIDUAL JOINT SWELLING.

D. Aletaha 1,*J. S. Smolen 2

1Department of Rheumatology, Medical University of Vienna, 2Department of Rheumatology, Medical University of Vienna and Hietzing Hospital Vienna, Vienna, Austria

 

Background: Remission in rheumatoid arthritis (RA) is usually defined as a state of no (or minimal) residual clinical disease activity and ideally should go along with maximal reduction of physical disability and halt of progression of joint damage. The Disease Activity Score employing 28 joint counts (DAS28) is frequently used to assess remission (DAS28<2.6), however, there is often residual disease activity in this state1. It is currently not known to which extent joint damage is retarded in DAS28 remission.

Objectives: To assess radiographic changes in DAS28 remission in RA patients with and without residual swollen joints (SJC).

Methods: We evaluated data from methotrexate (MTX) monotherapy arms of recent pivotal trials kindly provided by the respective sponsors (ASPIRE, ERA, Leflunomide, PREMIER, TEMPO). We pooled RA patients with complete clinical data at baseline, 6, 9 and 12 months, as well as X-ray data at baseline and 12 months (n=865). We identified patients who attained persistent DAS28 remission, defined as an average DAS28 from 6 to 12 months (DAS286-12) <2.6. For each of these patients, we calculated mean SJC for the 6-12 month period and then divided the patients into two groups, those with SJC6-12<2 and SJC6-12≥2. We assessed the radiographic progression of TSS from baseline to 12 months between patients with (SJC6-12≥2) and without (SJC6-12<2) residual joint swelling. We compared the proportion of patients progressing radiographically (increase of TSS score from baseline to 12 months of >0.52) by Chi2 statistics.

Results: 115 patients (13.3%) achieved DAS28<2.6; 22 of them (19%) had a mean SJC6-12≥2. DAS28 remitters without significant residual joint swelling (meanSJC6-12<2) showed a 1 year radiographic progression of 0.56±4.17, while those with residual swelling (meanSJC6-12≥2) progressed by 2.16±4.22 TTS points. The proportion of patients with a TSS progression >0.5 was significantly higher in patients with residual joint swelling (50.0%) compared to those without (23.9%; p=0.015). Residual SJC were decisive for damage progression in DAS28 remission, since neither DAS28 levels nor tender joint count or ESR influenced it in DAS28 remission (not shown). We then compared the DAS28 remission data with those using remission criteria of the simplified and clinical disease activity indices: in SDAI (≤3.3) and CDAI (≤2.8) remission no patient had SJC>2 and joint damage progressed only by means of 0.5±5.9 and 0.6±5.3, almost identical degrees as seen in DAS28 remitters who had no residual SJC. Interestingly, there were also significant differences in physical function: while HAQ was low in DAS28 remission (0.21±0.35), it was even lower in SDAI (0.09±0.18; p=0.0023) and CDAI remission (0.12±0.26; p=0.057).

Conclusion: A large proportion of patients in DAS28 remission not only have a significant residual swollen joint count but also significant progression of damage, indicating that more stringent criteria for remission are needed. SDAI and CDAI criteria were more stringent regarding progression of joint damage and residual disability.

 

References: (1) Makinen H et al Ann Rheum Dis 2005; 64:1410-1413; (2) van der Heijde D et al. Arthritis Rheum 2002; 47:215-218.

Acknowledgement. We thank Farideh Alasti for expert statistical support. We also thank Abbott, Amgen, Centocor, Sanofi-Aventis and Pfizer-Wyeth for kindly providing us with data of their clinical trials and Farideh Alasti for expert statistical support.

 

Disclosure of Interest: D. Aletaha Consultant for: Abbott, Schering-PloughJ. Smolen Grant / Research Support from: Abbott, Schering-Plough, Wyeth Consultant for: Abbott, Amgen, Centocor, Schering-Plough, Wyeth, Sanofi-Aventis